TGA / PMDA / NMPA · Asia-Pacific
group — TGA / PMDA / NMPA regulatory status
group regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 124 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 10-week smoking cessation group therapy combined with NicoDerm CQ | Phase 3 | BRIGHT MINDS BIOSCIENCES | NCT00110630 |
| 2.16/VI/22 | Phase 3 | Cardiol Therapeutics | 2023-503913-31-01 |
| 20190531 | Phase 3 | Amgen | 2023-503433-21-00 |
| 220030 | Phase 3 | GSK Glaxo Smith | 2024-519549-31-00 |
| Azacitidine Combined With Venetoclax and ATRA group | Phase 3 | First People's Hospital | NCT05654194 |
| C1091009 | Phase 3 | First Biotech (Australia) | 2022-503070-36-00 |
| GN41791 | Phase 3 | HOFFMANN-LA ROCHE | 2022-502611-10-00 |
| MCT8-2021-3 | Phase 3 | Rare Thyroid Therapeutics | 2024-516124-34-00 |
| MCV-ACYW135 Vaccine Group | Phase 3 | Beijing Luzhu Biopharmaceutical | NCT02003495 |
| MEQ00073 | Phase 3 | Sanofi Pasteur MSD | 2023-510145-25-00 |
| MEQ00074 | Phase 3 | Sanofi Pasteur MSD | NCT06228586 |
| MEQ00089 | Phase 3 | Sanofi Pasteur MSD | 2023-508177-85-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 2026029046 | LIPIDE D'URÉE OU DE CARBAMATE AYANT UN GROUPE CYCLIQUE DANS UNE CHAÎNE LATÉRALE, NANOPARTICULES LIPIDIQUES DE CELUI-CI ET COMPOSITION PHARMACEUTIQUE ASSOCIÉE | WO |
| 11813358 | Lipid nanodisc formation by polymers having a pendant hydrophobic group | US |
| 11793871 | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof | US |
| 11338033 | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof | US |
| 11191778 | Multifunctional linker technology containing an N4 group | US |
| 2019294474 | Pyridine derivatives substituted by heterocyclic ring and amino group | AU |
| 10760078 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | US |
| 10441607 | Multifunctional linker technology containing an N4 group | US |
| 10428200 | Immobilization of an active agent on a substrate using compounds including trihydroxyphenyl groups | US |
| 10202602 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | US |
| 10072122 | Carbonate polymer containing a functional group of disulfide five-membered ring in the side chain and application thereof | US |
| 9950001 | Polynucleotides having bioreversible groups | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of group?
group currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get group regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to group?
This spoke lists 124 published programs associated with group in our pipeline index.